Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
JETi™ Hydrodynamic Thrombectomy System
Single-session treatment of lower extremity venous thrombosis using a novel thrombectomy device

Request a hands-on demonstration

Single-session treatment of lower extremity venous thrombosis using a novel thrombectomy device

Overview: Retrospective Pilot Study

Khalsa et al., JVIR. 2020.

Objective
To study the efficacy of the JETi™ Peripheral Thrombectomy System in treating acute venous thrombosis.

Methods
Retrospective review of 40 total procedures in 30 patients with acute lower extremity venous thrombosis (25 iliocaval, 20 iliofemoral and 15 femoropopliteal segments).

Primary Endpoints
Technical Success Rate defined as reestablishment of inline flow.

Additional Endpoints
Percent thrombus removal, total thrombolytic dose, total procedural time, overnight thrombolysis post procedure, ICU length of stay, total hospital length of stay, procedure related complications, mean symptom duration and venous segments treated.

Clinical Outcomes

JETi™ Peripheral Thrombectomy System achieved a 93% overall technical success rate with 77% of patients successfully treated in a single-session. Patients treated with JETi™ in a single-session required less TPA and shorter ICU stays compared to those treated with overnight CDT. 

  Single-Session JETi™ Thrombectomy
(n = 23/30)		 Overall JETi™ Thrombectomy*
(n = 30/30)
Mean ICU Length of Stay 1.1 days 1.6 days
Mean TPA Dose 3.1 mg 7.8 mg
Mean Thrombus Removal 81.2% 74.0%

*Data includes 7 patients requiring overnight CDT.

Restoration of inline flow was successfully achieved in 77% of patients in a single session.

JETI Restoration of Inline Flow

Single-session restoration of flow was associated with shorter ICU stays and a 60% lower dose of TPA when compared with overnight CDT.

JETi Shorter ICU Stays and Lower TPA Data

Technical success was achieved in 93% of patients treated with the JETi™ Thrombectomy System.

JETi Technical Success Data for Lower Extremity Venous Thrombosis
Request a Demo

Reference:

Khalsa et al., JVIR. 2020.

MAT-2209358 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo